Track topics on Twitter Track topics that are important to you
IntraCellular Therapies Inc ITI is a biopharmaceutical company that discovers and develops novel drugs for the treatment of neuropsychiatric and neurologic disorders. The company's lead product candidate include ITI007lumateperone, which is intended for the treatment of schizophrenia, behavioral disturbances in dementia, sleep and behavioral disturbances associated with autism spectrum disorder, other mood disorders, sleep disturbances associated with neurologic and psychiatric disorders, and others. Its lead candidate lumateperone is in phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia and alzheimer's disease. The company utilizes phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. ITI is headquartered in New York, the US.
IntraCellular Therapies Inc Key Recent Developments
May 10,2017: IntraCellular Therapies Reports First Quarter 2017 Financial Results and Provides Corporate Update
Mar 01,2017: IntraCellular Therapies Reports Fourth Quarter and FullYear 2016 Financial Results and Provides Corporate Update
Nov 09,2016: IntraCellular Therapies Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Aug 04,2016: IntraCellular Therapies Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Apr 28,2016: IntraCellular Therapies Reports First Quarter 2016 Financial Results and Provides Corporate Update
This comprehensive SWOT profile of IntraCellular Therapies Inc provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of IntraCellular Therapies Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends.
The profile contains critical company information including*, x000D
Business description A detailed description of the company's operations and business divisions.x000D
Corporate strategy Analyst's summarization of the company's business strategy.x000D
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D
Company history Progression of key events associated with the company.x000D
Major products and services A list of major products, services and brands of the company.x000D
Key competitors A list of key competitors to the company.x000D
Key employees A list of the key executives of the company.x000D
Executive biographies A brief summary of the executives' employment history.x000D
Key operational heads A list of personnel heading key departments/functions.x000D
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D
Key manufacturing facilities A list of key manufacturing facilities of the company.x000D
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D
Note*: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,x000D
You get detailed information about the company and its operations to identify potential customers and suppliers.x000D
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D
Gain key insights into the company for academic or business research.x000D
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Schizophrenia is a common serious long-term mental health condition that affects 5 in 1000 in the UK. It causes a range of different psychological symptoms; hallucinations, delusions, muddled thoughts based on the hallucinations or delusions and ch...
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase 'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...